Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing a stable cell line expressing recombinant sclerostin

Award Number: SB1DE031481
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2022
PERIOD OF PERFORMANCE END DATE: 09/16/2024

Group Awards By:

View Award Description

Developing a stable cell line expressing recombinant sclerostin - 1 Abstract 2 The temporomandibular joint (TMJ) is a complex joint system critical for dental occlusion, 3 mastication, respiration and speech. The TMJ is comprised of a network of muscles, 4 ligaments, and a fibrocartilaginous disc and condyle. Temporomandibular disorders (TMDs) 5 are a complex, heterogeneous group of pathologies involving the TMJ and associated 6 musculature. Degenerative types of TMDs, including TMJ osteoarthritis (OA), are debilitating, 7 compromise the quality of life. TMDs afflict over 10 million Americans at an annual cost of 8 ~$4 billion, per the NIDCR. Current TMJ OA treatments are typically two-fold, involving either 9 pain management or invasive surgeries, such as total joint replacements with high failure rates. 10 Regenerative medicine promises the recreation functional tissue that is lost from diseases. 11 Thus exploiting the regenerative capabilities of resident stem cells to repair TMJ may 12 represent a minimally invasive stem cell based treatment for TMJ OA. Sponsored by NIH 13 small business grant, we further developed StemGel®, a sustained-release formulation by 14 encapsulating sclerostin in hyaluronic acid (HA). Monthly injection of StemGel® efficiently 15 inhibits TMJ OA progression and regenerates cartilage in both rabbit and minipig TMJ OA 16 models. 17 The active ingredient of StemGel®, sclerostin is a glycosylated protein with 213 amino acids. 18 A mammalian expressing system is required to faithfully produce the post-translational 19 modification. Cell line development is a critical inflection point for therapeutic protein 20 manufacturing. The properties of the cell substrate and the events linked to cell substrate 21 can affect protein quality and safety, and further, the effective quality control on all aspects of 22 handling the cell substrate. The goal of this proposal is to develop Master Cell Bank 23 (MCB)/stable cell line expressing sclerostin to be readily transferred to the Contract 24 Development and Manufacturing Organization (CDMO) for massive production of the GMP 25 grade protein for pharmacokinetics and safety tests.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	WNT SCIENTIFIC LLC	156 RALEIGH ST	ROCHESTER	NY	14620	MONROE	USA	Oral Diseases and Disorders Research	000	1	5/7/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	WNT SCIENTIFIC LLC	156 RALEIGH ST	ROCHESTER	NY	14620	MONROE	USA	Oral Diseases and Disorders Research	000	1	11/8/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	WNT SCIENTIFIC LLC	156 RALEIGH ST	ROCHESTER	NY	14620	MONROE	USA	Oral Diseases and Disorders Research	000	1	11/4/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $290,002 )
2022	2022	WNT SCIENTIFIC LLC	156 RALEIGH ST	ROCHESTER	NY	14620	MONROE	USA	Oral Diseases and Disorders Research	000	1	9/20/2022	NEW	$290,002
														Subtotal = $290,002

Grand Total All Awards = $290,002

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing a stable cell line expressing recombinant sclerostin

Award Number: SB1DE031481

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2022

PERIOD OF PERFORMANCE END DATE: 09/16/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer